Oncology
 |
|
20 march 2019 04:03:11 |
| Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale (Future Oncology) |
|
Tweet Future Oncology, Volume 15, Issue 9, Page 929-941, March 2019. |
| 45 viewsCategory: Oncology |
 Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma? (Future Oncology)KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer (Future Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
